Treatment of Lynch Syndrome: Surveillance Colonoscopy and Cancer Prevention

Persons with Lynch syndrome face an elevated risk of colorectal cancer and require a structured management plan. This protocol addresses the evidence-based approach to surveillance and cancer prevention recommended for this population.

Clinical Scenario

Lynch syndrome — ongoing management with emphasis on colorectal cancer surveillance and the role of cancer-preventive intervention alongside colonoscopy.

Management Approach

The protocol involves regular surveillance colonoscopy combined with aspirin offered for cancer prevention. The complete protocol specifies the surveillance intervals, eligibility criteria, and the evidence base for each component.

Full schedule, dosing, and decision criteria are in the structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1053/j.gastro.2015.07.036

The AGA recommends surveillance colonoscopy (versus doing nothing) in persons with Lynch syndrome.

The AGA suggests that surveillance colonoscopy should be performed every 1 to 2 years versus less frequent intervals.

The AGA suggests that aspirin be offered for cancer prevention in patients with Lynch syndrome.

One high-quality randomized controlled trial in adults with Lynch syndrome assessed the antineoplastic effect of aspirin 600 mg daily compared with placebo over a period up to 4 years and showed a decreased incidence of colorectal cancer beyond that with colonoscopy surveillance alone.

View source ↗